Novavax Inc. ($NVAX) Stock Forecast: Up 5.4% Today

What is Novavax Inc.?

Novavax (NVAX) is a biotechnology company focused on developing vaccines for infectious diseases. The overall market sentiment is bullish today.

Why is Novavax Inc. going up?

NVAX stock is up 5.4% on Jul 2, 2025 14:10

• NVAX stock experienced a bearish movement, decreasing by -2.15%.
• The positive market sentiment did not reflect on NVAX, suggesting company-specific factors influenced the stock's decline.
• Investors might be reacting to recent news or developments within NVAX, leading to the downward movement despite the overall bullish market trend.
• Traders should keep an eye on upcoming announcements or updates from NVAX to better understand the stock's performance in the near future.

NVAX Price Chart

NVAX Technical Analysis

NVAX News

Ginkgo Bioworks ( DNA ) Soars 18.9%: Is Further Upside Left in the Stock?

Ginkgo Bioworks (DNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

https://www.zacks.com/stock/news/2559125/ginkgo-bioworks-dna-soars-189-is-further-upside-left-in-the-stock

Novavax ( NVAX ) Stock Slides as Market Rises: Facts to Know Before You Trade

The latest trading day saw Novavax (NVAX) settling at $6.36, representing a -2.15% change from its previous close.

https://www.zacks.com/stock/news/2556467/novavax-nvax-stock-slides-as-market-rises-facts-to-know-before-you-trade

Trending Today

Cardano ($ADA) Crypto Forecast: Down 5.1% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.0% Today

Novavax Inc. Price History

08.04.2025 - NVAX Stock was up 13.9%

• Novavax (NVAX) saw a substantial bullish upturn after exceeding earnings and revenue expectations by a significant margin in the first quarter.
• The market responded favorably to Novavax's exceptional quarterly earnings and revenue beat, indicating investor trust in the company's progress and future prospects.
• The upbeat financial outcomes and potential pipeline advancements announced during the earnings call likely contributed to the positive momentum in NVAX stock.
• In conclusion, Novavax's strong performance and optimistic market sentiment steered the stock towards a bullish path, underscoring the company's resilience and growth potential within the biotechnology industry.

08.04.2025 - NVAX Stock was up 16.2%

• Novavax (NVAX) exceeded both earnings and revenue estimates for the first quarter of 2025, showcasing strong financial performance.
• The positive earnings surprise likely boosted investor confidence in the company's growth prospects, leading to the bullish movement in the stock.
• Investors are eagerly awaiting pipeline updates from Novavax, indicating optimism about the company's future projects and potential market impact.
• The flat performance of Novavax in the previous trading session amidst overall market gains suggests that today's bullish movement was primarily driven by the impressive earnings report rather than broader market trends.

19.04.2025 - NVAX Stock was down 5.6%

• The company received limited approval from the FDA for its COVID-19 vaccine, Nuvaxovid, with restrictions on usage for specific age groups and high-risk individuals.
• Despite securing FDA approval, the stock faced a bearish trend, possibly due to concerns about the limited target population for the vaccine.
• The milestone payment of $175 million from partner Sanofi SA did not seem to have a positive impact on the stock's performance.
• The market may be reacting to the news of FDA approval with new conditions, leading to uncertainty about the vaccine's widespread adoption and revenue potential.

19.04.2025 - NVAX Stock was down 6.7%

• Novavax's stock experienced a bearish movement despite the FDA granting limited approval for its COVID-19 vaccine.
• The restricted use of the vaccine to specific age groups and high-risk individuals might have raised concerns about the company's market potential and revenue prospects.
• Investors may be disappointed by the limited scope of the FDA approval, leading to a sell-off of NVAX shares as they reassess the company's position in the competitive vaccine market.
• The market reaction suggests that investors were expecting broader approval for Novavax's vaccine, and the current restrictions could impact the company's ability to capture a larger market share and generate significant revenue.

09.04.2025 - NVAX Stock was down 12.2%

• Novavax (NVAX) reported impressive first-quarter earnings and revenue beats, with a significant increase in revenues recognized from the termination of advanced purchase agreements.
• Despite the positive financial results, the market may have reacted bearishly due to profit-taking after a recent rally in the stock price.
• Investors might be uncertain about the stock's future performance, considering the focus on pipeline updates during the earnings call and the overall market sentiment.

02.06.2025 - NVAX Stock was up 5.4%

• NVAX stock experienced a bearish movement, decreasing by -2.15%.
• The positive market sentiment did not reflect on NVAX, suggesting company-specific factors influenced the stock's decline.
• Investors might be reacting to recent news or developments within NVAX, leading to the downward movement despite the overall bullish market trend.
• Traders should keep an eye on upcoming announcements or updates from NVAX to better understand the stock's performance in the near future.

21.04.2025 - NVAX Stock was down 5.5%

• Novavax's stock saw a decline despite obtaining FDA approval for its COVID-19 vaccine, Nuvaxovid, which received limited approval specifically for high-risk groups and seniors.
• The FDA's decision to restrict annual COVID-19 booster approvals to high-risk individuals and request further trials for healthy adults may have influenced investor sentiment negatively towards Novavax's stock.
• The market's response could be linked to the stricter clinical trial standards set by the FDA, potentially causing concerns about Novavax's upcoming vaccine projects and commercialization prospects.
• Despite achieving a regulatory milestone and receiving a milestone payment from partner Sanofi SA, the market's emphasis on limited approval and safety evaluations likely contributed to the bearish movement in NVAX stock.

17.05.2025 - NVAX Stock was down 5.1%

• Despite promising results indicating a robust immune response in seniors from Novavax's COVID-flu combo shot, the stock trended bearishly.
• Investor profit-taking, following a recent uptick in the stock price, may have contributed to the negative market reaction.
• Concerns about Novavax's capability to effectively launch and compete with other vaccine producers in the market might have influenced investor sentiment.
• The stock's decline could also reflect broader market trends or sector rotations affecting biotechnology companies.

28.04.2025 - NVAX Stock was down 5.1%

• The decline in NVAX stock could be attributed to heightened competition and uncertainty in the vaccine sector.
• Moderna's submission to the FDA for an enhanced COVID-19 vaccine tailored to a prevalent variant might have sparked concerns about Novavax's market position and competitiveness.
• Additionally, the retraction of Moderna's FDA submission for a COVID-flu combination vaccine could have contributed to the pessimism surrounding vaccine stocks, including NVAX.
• In general, the updates and setbacks in the vaccine field related to Moderna may have eclipsed Novavax's performance, resulting in a negative shift in NVAX stock.

06.04.2025 - NVAX Stock was down 6.9%

• Novavax (NVAX) saw significant bearish movement today, potentially a result of profit-taking following recent gains or concerns about the upcoming earnings.
• Investors may have responded unfavorably to the lack of substantial changes in NVAX's stock price yesterday, leading to increased selling activity.
• Expectations may have been elevated due to focus on pipeline updates during the earnings call, and any perceived shortcomings in those updates could have contributed to the market downturn.
• Although market gains were stagnant, the decrease in NVAX's stock price may also reflect broader investor sentiment towards the biotechnology field and vaccine stocks as a whole.

24.05.2025 - NVAX Stock was up 5.1%

• NVAX displayed a notable upward trend, ending at $6.41 with a +1.75% rise compared to the previous day.
• This positive momentum in NVAX could be linked to advancements in vaccine development or favorable updates on their clinical trials.
• Despite the market's decline, NVAX's performance reflects investor confidence in its future potential.
• Investors seem hopeful about NVAX's capacity to tackle global health issues, contributing to the stock's upward trajectory.

29.03.2025 - NVAX Stock was down 7.0%

• The bearish movement in NVAX stock today could be attributed to the request for new trials for Novavax's COVID vaccine by former FDA appointees, possibly causing a delay in approval.
• Despite the recent positive developments and surge in NVAX stock price, uncertainty around the new clinical trials request may have unsettled investors, resulting in the downward trend.
• Investors seem wary of the potential consequences of a delayed approval and its effects on Novavax's competitiveness in the COVID-19 vaccine market, adding to the stock's downward pressure.